User profiles for Neil Chanchlani
 | Neil ChanchlaniExeter IBD Pharmacogenetics Verified email at doctors.org.uk Cited by 2106 |
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
…, R Nice, MH Perry, S Bouri, N Chanchlani… - The lancet …, 2019 - thelancet.com
Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for
a lower level of immunity across more of the population. We investigated whether patients …
a lower level of immunity across more of the population. We investigated whether patients …
[HTML][HTML] HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease
Background & Aims Anti–tumor necrosis factor (anti-TNF) therapies are the most widely
used biologic drugs for treating immune-mediated diseases, but repeated administration can …
used biologic drugs for treating immune-mediated diseases, but repeated administration can …
[HTML][HTML] Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with …
…, FP Pieper, KM Lin, DK Butler, N Chanchlani… - Nature …, 2022 - nature.com
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
and impair protective immunity following pneumococcal and influenza vaccination. Here we …
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
…, C Bewshea, R Nice, D Chee, S Lin, N Chanchlani… - Gut, 2021 - gut.bmj.com
Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …
[HTML][HTML] Addressing the indirect effects of COVID-19 on the health of children and young people
… Contributors: Neil Chanchlani and Peter Gill contributed to the conceptualization and wrote
the … Disclaimer: Neil Chanchlani is an associate editor for CMAJ and was not involved in the …
the … Disclaimer: Neil Chanchlani is an associate editor for CMAJ and was not involved in the …
Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients
Background and Aims Infliximab attenuates serological responses to SARS-CoV-2 infection.
Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences …
Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences …
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Objective Antitumour necrosis factor (TNF) drugs impair serological responses following
SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-…
SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-…
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have …
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have …
[HTML][HTML] Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS …
N Chanchlani, S Lin, C Bewshea… - The Lancet …, 2024 - thelancet.com
Background We sought to report the effectiveness of infliximab and adalimumab over the first
3 years of treatment and to define the factors that predict anti-TNF treatment failure and the …
3 years of treatment and to define the factors that predict anti-TNF treatment failure and the …